Opinion|Videos|July 24, 2024
EHA 2024 Highlights: Overcoming Challenges with Bispecific Antibodies in RRMM
Author(s)Joseph Mikhael, MD
Dr. Mikhael outlines the significant hurdles in bispecific antibody therapy, as presented at the European Hematology Association's 2024 conference.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- Results from the phase 1/2 MonumenTAL-1 study and phase 1B MonumenTAL-2 study were also presented at EHA 2024. How do the results from these two trials contribute to the evolving role of talquetamab in multiple myeloma?
- What is the value of long-term follow-up data in multiple myeloma? How does this impact use of treatment regimens?
- What challenges must be considered and overcome with bispecific antibody-containing regimens in RRMM?
Advertisement
Related to this article
HYPERION trial data shows a 76% reduction in clinical worsening events among adults recently diagnosed with PAH.
Diabetes care improves when support adapts to real-life changes, removing barriers and sustaining daily habits beyond reminders, education, and one-time interventions.
Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Global Burden of Disease data show prevalence fell nearly 30% from 1990 to 2021, yet the number of women affected grew 9.1%.
Logistic regression beats machine learning to predict autoimmune hepatitis recurrence after liver transplantation.
A new blood test for adults as young as 40 years arrives as employers and insurers still treat Alzheimer disease as an old-age condition.
Itch and skin appearance outranked safety for 300 US adults with chronic hand eczema, but cancer risk came next.
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Treatment for Sanfilippo Syndrome Type A
2
No Blood Biomarker Is Ready to Pick Psoriasis Therapy
3
Real-World Data: FACT vs Non-FACT CAR T Outcomes Compared
4
World Alzheimer Day: Young-Onset Alzheimer Disease Often Misdiagnosed
5